Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. (CVSI) operates at the intersection of scientific innovation and natural wellness, developing hemp-derived supplements and plant-based nutrition solutions. This page serves as the definitive source for official company announcements, research breakthroughs, and operational developments.
Investors and industry stakeholders will find curated updates spanning regulatory milestones, product launches, and peer-reviewed studies validating CVSI's formulations. The archive includes earnings reports, manufacturing expansions, and clinical trial outcomes supporting their +PlusCBD and Cultured Foods brands.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards and scientific accuracy. Users can efficiently track the company's progress in obtaining self-affirmed GRAS statuses, scaling global distribution networks, and advancing pet wellness innovations.
Bookmark this resource for real-time access to CV Sciences' advancements in cannabinoid research, nutraceutical safety protocols, and strategic partnerships within the consumer health sector. Regularly updated to reflect the company's evolving role in science-driven wellness solutions.
CV Sciences (OTCQB:CVSI) announced it will release its second-quarter financial results on August 12, 2021, after market close. A conference call for investors is scheduled the same day at 1:30 PM PT. The call will be accessible via the company's Investor Relations webpage and will be archived for 30 days. CV Sciences operates two divisions: a consumer product segment focused on CBD products and a drug development segment for CBD-based therapeutics. Its PlusCBD™ brand is recognized as a leader in the natural products market.
CV Sciences, Inc. (OTCQB:CVSI) announced that its CV™ Defense product received the 2021 Product of the Year: Immune Support Award from NutraIngredients-USA. This award recognizes innovation in nutrition and dietary supplements. CV™ Defense contains ingredients like PEA, reishi mushroom extract, vitamins A and D, selenium, and zinc, aimed at enhancing immune health. The award underscores the company's commitment to expanding its product portfolio beyond CBD, reflecting strong initial sales and consumer demand for effective wellness products.
CV Sciences announced progress in developing a CBD-based pharmaceutical for nicotine addiction in collaboration with UC San Diego. A preclinical study revealed that chronic CBD treatment significantly reduced withdrawal symptoms in nicotine-dependent rats. This research highlights CV Sciences' commitment to addressing the $2 billion smokeless tobacco addiction market, with potential FDA-approved treatment in development. The company has secured a patent for a proprietary CBD and nicotine formulation, further expanding its product development opportunities.
CV Sciences (CVSI) reported Q1 2021 revenue of $4.8 million, a 41% decrease from $8.3 million in Q1 2020, attributed to the ongoing COVID-19 pandemic and increased market competition. Despite this, the gross margin slightly improved to 48.7% from 48.5% year-over-year. The company’s cash balance rose to $5.7 million, up from $4.5 million at year-end. Retail distribution expanded to over 7,300 stores, up from 5,799 a year prior. New product launches, including ProCBD™ and PlusCBD™ Calm and Sleep gummies, were well received, indicating potential future growth.
CV Sciences has launched new PlusCBD™ Calm and Sleep gummies aimed at supporting healthy stress responses and sleep cycles. Each gummy contains 10mg of CBD, plus 5-HTP and L-Theanine for Calm, and melatonin, magnolia bark, and lemon balm for Sleep. These products promise no artificial additives and are third-party tested for quality. CV Sciences emphasizes its commitment to scientifically formulated products backed by clinical research, available for purchase online and in retail later this year.
CV Sciences (OTCQB:CVSI) will announce its financial results for Q1 2021 on May 13, 2021, after market close. A conference call to discuss these results is scheduled for 1:30 PM PT (4:30 PM ET) on the same day. Access to the call will be available through the Company’s Investor Relations webpage, with a replay offered two hours post-call until May 20, 2021. CV Sciences operates in two sectors: consumer products and drug development, with its PlusCBD™ products leading the hemp-derived CBD market across over 7,300 retail locations in the U.S.
CV Sciences (OTCQB: CVSI) has announced a partnership with Alkemist Labs to support the National Institute of Standards and Technology (NIST) in enhancing cannabis testing methodologies. This collaboration aims to improve measurement accuracy for cannabis products, crucial for legal and safety claims. CV Sciences will provide hemp oil samples for testing, and Alkemist Labs will measure cannabinoid levels. NIST’s Canna Quality Assurance Program (CannaQAP) will benefit various laboratories and researchers in the cannabis industry.
CV Sciences reported financial results for the year ended December 31, 2020, with revenues of $24.4 million, a 55% decline from $53.7 million in 2019. The gross margin stood at 45.1%, while the cash balance remained stable at $4.5 million. The company expanded its retail distribution to over 7,300 stores, up from 5,500 the previous year. Despite these advancements, an operating loss of $22.6 million was reported, marking an increase from $17.2 million in 2019, and a negative adjusted EBITDA of $11.6 million.
CV Sciences, Inc. (OTCQB:CVSI) will release its financial results for the fiscal year and fourth quarter ending December 31, 2020, on March 18, 2021. The company will conduct a conference call on the same day at 1:30 p.m. PT, which can be accessed via the Investor Relations section of its website. The PlusCBD™ brand leads the hemp-derived CBD market in over 7,300 retail locations and is compliant with Good Manufacturing Practices (GMP). The company emphasizes its commitment to scientific research in support of its products.
CV Sciences has announced a major refresh of its PlusCBD™ product line, introducing over 30 new products in the next 45 days. The updated line features contemporary packaging and innovative products such as extra strength gummies and softgels. Each product now includes a QR code linking to lab reports, ensuring quality assurance. According to CEO Joseph Dowling, extensive market research led to this redesign aimed at broadening consumer appeal and reinforcing brand equity. PlusCBD™ remains the top-selling CBD brand, derived from sustainable U.S. and EU hemp.
